377 results about "Aceglatone" patented technology

The invention discloses a composition for improving the stability of oleuropein in a solution as well as a preparation method and application of the composition. The composition comprises oleuropein and at least one stabilizer, and the stabilizer is selected from the group consisting of anisic acid, lactobionic acid, glycyrrhizic acid, 3, 3-thiodipropionic acid, N-acetyl-L-glutamine, propyl-cysteine and lauramidopropyl betaine; and the pH value of the aqueous solution of the composition is 4.0-8.0. The preparation method comprises the following steps: dissolving oleuropein in water, adding the stabilizer, and uniformly mixing. Through simple physical mixing, by utilizing the synergistic effect of the specific stabilizer and the oleuropein, the degradation and discoloration of the oleuropein in the storage process are remarkably inhibited. Experiments show that after the preferable composition is preserved for 30 days in an open manner, the retention rate of the oleuropein still reaches up to 80% or above, and is far superior to that of blank control and a traditional liposome wrapping method. The composition is simple and convenient in preparation process and low in cost, and provides reliable technical support for wide application of oleuropein in liquid products such as food, medicine and cosmetics.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant escherichia coli for efficiently producing O-acetyl-L-homoserine as well as a construction method and application of the recombinant escherichia coli. According to the invention, CRISPR-Cas9 gene editing is combined with metabolic modification, so as to precisely integrate OAH biosynthesis key nodes: introducing and overexpressing a mutant metX gene at a genome pseudogene site to enhance the expression of homoserine acetyltransferase, knocking out byproducts such as poxB and mgsA to synthesize genes, and carrying out high-yield synthesis of OAH. Corynebacterium glutamicum thrA (anti-feedback inhibition), aspB and bacillus subtilis acsA-acuA genes (construction of an acetic acid switch) are introduced, gene expression of gltA, tpiA and the like is optimized to increase supply of precursors such as acetyl CoA and the like, and finally a stable strain without plasmids, antibiotics and inducers is obtained. The production cost is effectively reduced, and the method has the advantage of high genetic stability and shows a good application prospect in OAH industrial production.

The invention relates to a culture medium for high-density serum-free suspension culture of BHK-21 cells and application of the culture medium. The culture medium contains inorganic salt, amino acid, vitamins, energy substances, a buffer substance, an antioxidant, sterol, polyamine, an additive and an indicator, and the antioxidant comprises dihydrolipoic acid and S-acetyl-L-glutathione. According to the invention, the culture medium for serum-free suspension culture of the BHK-21 cells, which is clear in components and remarkable in culture effect, can be provided. The added dihydrolipoic acid and S-acetyl-L-glutathione are combined as antioxidants of the culture medium, so that the survival rate of BHK-21 cells cultured in the culture medium is improved while the oxidation resistance of the serum-free suspension culture medium is improved.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention discloses an N-acetylglucosamine transferase AcetRS-K23G and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the N-acetylglucosamine transferase AcetRS-K23G is as shown in SEQ ID NO. 3. The invention further discloses an application of the N-acetylglucosamine transferase AcetRS-K23G in the preparation of the chitosan oligosaccharide. The N-acetylglucosamine transferase AcetRS-K23G disclosed by the invention is obtained by performing mutation modification on the N-acetylglucosamine transferase AcetRS, and can be used for producing the chitosan oligosaccharide with the polymerization degree of 5-7, especially the heptaose, the yield of the heptaose can reach 42.01 mg / L, and the N-acetylglucosamine transferase AcetRS-K23G is an ideal functional enzyme for industrially producing the heptaose. The product spectrum of the N-acetylglucosamine transferase is widened, and the N-acetylglucosamine transferase can be used for preparing high-polymerization-degree chitosan oligosaccharide and has a wide application prospect.

The invention relates to a gastric acid-resistant sustained-release intestinal bacteria capsule based on bionic mucous membrane-enzymolysis response and a preparation method thereof. The gastric acid-resistant sustained-release intestinal bacteria capsule comprises a core layer, an adhesive layer, an outer-layer composite film and a protective coating from inside to outside, the core layer consists of intestinal flora and a multifunctional freeze-drying protective agent; the adhesive layer is composed of trehalose, N-acetyl glucosamine and MUC2 recombinant protein; the outer-layer composite film is composed of a base material and a functional filler; the protective coating is composed of beewax and chitosan. The anti-gastric acid sustained-release intestinal bacteria capsule based on bionic mucosa-enzymolysis response provided by the invention has excellent gastric acid resistance, and the gastric acid resistance is remarkably improved; good slow release performance is achieved, and accurate slow release of enzymatic hydrolysis response can be achieved; the colonization efficiency of the intestinal bacteria can be effectively improved; the storage stability is good. The preparation method provided by the invention has the advantages of simplified steps, short time consumption, controllable core operation time and obviously shortened whole process, and is beneficial to keeping the activity of the flora.

The invention provides a chemical synthesis method of a TIMP2 protein N-terminal structural domain. An amino acid sequence of an N-terminal structural domain of TIMP2 protein is divided into four segments, the four segments are synthesized by a solid-phase polypeptide synthesis method, full-length linear polypeptide is obtained through natural chemical connection, sulfur removal and sulfydryl removal and acetamino methyl removal, finally impurities in a system are removed, the full-length linear polypeptide is dropwise added into a refolding reaction system, oxidation and refolding reactions are carried out, and the TIMP2 protein is obtained. A target product is obtained. The N-TIMP2 of the N-terminal structural domain of the TIMP2 retains the inhibitory activity of the TIMP2 on the MMP14, the N-TIMP2 obtained through chemical total synthesis can introduce non-natural amino acid to any site in the sequence or perform specific modification or mutation in the synthesis process, an effective tool is provided for researching the specific action mechanism of the N-TIMP2 and the MMP14, and a foundation is further laid for research and development of the MMP14 inhibitor.

Cosmetic method for improving skin characteristics, in which the cleansed skin surface is sprayed with water containing four-atom oxygen, known in itself as activated stabilized oxygen, and then, after the skin has absorbed the spray, the surface is coated with a preparation containing at least 0.040% by weight of hydrolyzed beta-glucan, preferably 0.1% by weight, wherein the preparation also contains at least 0.04% by weight, preferably 0.1 w% acetyl tetrapeptide-40, in the form of a gel or cream, and then the pretreated skin surface is irradiated with soft laser light emitting scattered rays with a wavelength of 700-900 nm and a power density of 40-200 mW cm2 power density, where the irradiation time is at least 30 seconds, depending on the power density. The composition contains at least 0.040% by weight of hydrolyzed beta-glucan, 1-5% by weight of a moisturizing agent, 15-20% by weight of a skin conditioning agent, 1-5% by weight of a preservative, and at least 0.04% by weight of acetyl tetrapeptide-40.

Compounds and compositions comprising compounds that modulate histone acyltransferase (HAT). Methods of treating neurodegenerative disorders, conditions associated with amyloid-beta peptide deposit accumulation, Tau protein levels, and / or alpha-synuclein accumulation, and cancer by administering to a subject a compound that modulates HAT.

The invention discloses a liver-protecting beverage containing a composite plant exosome with optimized antioxidant capacity. The liver-protecting beverage comprises a plant exosome solution and a liver-protecting component, the plant exosome solution is a silybum marianum exosome solution and at least two of a Pingyin red rose exosome solution, a radix puerariae exosome solution, a turmeric exosome solution and a dandelion exosome solution; the liver protection component is at least one of silybum marianum micro-capsule powder, a radix puerariae extract, corn peptide, a dandelion extract and S-acetyl-L-glutathione. Hydroxyl and amido on small molecules are combined with lipid structures on the surfaces of multiple plant exosomes, small molecule active ingredients are combined through adsorption or reaction on the surfaces of the lipid structures of the exosomes, the oxidation resistance of the product can be improved, absorption of intestinal cells and probiotics is facilitated, cell metabolism is promoted, and then the fatigue feeling is reduced.

This invention provides a method for the simultaneous and rapid detection of four oxidative stress-related biomarkers and its application. The detection method includes: (S1) pretreatment of samples using a protein precipitation extract to simultaneously extract four target compounds: 8-hydroxydeoxyguanosine, 8-isoprostaglandin F2β, 8-isoprostaglandin F2α, and acetyllysine, and preparing a test solution; the protein precipitation extract is a methanol-acetonitrile-perchloric acid mixed solution containing formic acid, wherein the volume ratio of methanol, acetonitrile, and perchloric acid is (8-10):(8-10):(0.5-1), and the volume concentration of formic acid is 0.1-0.5%; (S2) detection of the test solution and standard solution using liquid chromatography-tandem mass spectrometry, and matrix calibration using an internal standard method; plotting a standard curve with the peak area ratio of the target compound to the internal standard as the ordinate and the concentration as the abscissa; and calculating the concentration of the target compound in the test solution based on the standard curve.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

A method for separately quantifying N-acetylcysteine and glutathione in brain tissue includes administering N-acetylcysteine to a subject, acquiring a first magnetic resonance spectroscopy signal from a region of brain tissue of the subject, the first magnetic resonance spectroscopy signal comprising a cysteine β-proton signal, acquiring a second magnetic resonance spectroscopy signal from the region of brain tissue, the second magnetic resonance spectroscopy signal comprising an N-acetyl proton signal, and determining a concentration of N-acetylcysteine in the region of brain tissue based on the N-acetyl proton signal and determining a concentration of glutathione in the region of brain tissue based on a difference between the cysteine β-proton signal and the N-acetyl proton signal.

The invention relates to the technical field of artificial design of enzymes, in particular to an artificial intelligence design and expression system construction method and system for lysosomal membrane protein type N-acetyltransferase with 11 transmembrane regions, and the method comprises the following steps: collecting reaction rate information of an enzyme and a substrate, associating a structure model with rate parameters, and comparing three-dimensional difference of residues, according to the method, by collecting the reaction rate correlation structure conformation, dynamic recognition of the key conformation state is achieved, the accuracy of three-dimensional space difference analysis is improved, host expression optimization factors are fused in the construction process, and the construction efficiency is improved. According to the method, the expression efficiency is improved, conformation function screening and structural stability parallel evaluation are carried out, the screening accuracy of efficient catalysis and stable expression is enhanced, three links of recognition, screening and construction are broken through, the target enzyme obtaining efficiency and expression quality are improved, and enzyme engineering is promoted to be developed towards high-throughput systematization.

The invention discloses selenoglycoside gligliflozin as well as a preparation method and application thereof. The structural formula of the selenoglycoside gligliflozin disclosed by the invention is shown as a formula (I). The preparation method of the seleno-glucoside gliflozin comprises the following steps: 1, directly carrying out selenium-carbon coupling reaction on peracetyl-protected 1-seleno-glucose in a solvent under the action of alkali and a palladium catalyst to prepare tetra-acetyl-protected seleno-glucoside gliflozin; and step 2, carrying out deacylation on the tetra-acetyl protected seleno-glucoside gliliflozin product to prepare the seleno-glucoside gliliflozin. A biological activity test shows that the selenoglycoside gliliflozin provided by the invention shows low toxicity to cells, high inhibitory activity to SGLT-2 (sodium glucose transporter 2) and beta-glucosidase hydrolysis resistance, so that the selenoglycoside gliliflozin has the potential to be developed into a medicine for treating diabetes mellitus 2. (I)

A modified hyaluronic acid derivative is described having the —CH2-OH group of the N-acetyl-D-glucosamine unit (GlcNAc) modified to an aldehyde group having the structure —CH2-O—CH2-CHO where the degree of modification is 1.0% to 15.0% for preparing a crosslinked hydrogel for use in aesthetic applications. The modified hyaluronic acid derivative is prepared by reacting a glycerol-modified hyaluronic acid with an oxidizing agent such as periodate.

The invention provides a method for treating autoimmune diseases mediated by regulatory T cell (Treg) programmed necrosis. Specifically, the invention provides application of an O-linked beta-N-acetylglucosamine glycosylation (O-GlcNAcylation) accelerant, and the O-linked beta-N-acetylglucosamine glycosylation accelerant is used for preparing a medicine or a preparation for treating programmed necrosis type autoimmune diseases. It is found for the first time that when the O-GlcNAcylation promoter is used for improving the O-GlcNAcylation level of RIPK1 / 3 protein, Treg programmed necrosis can be effectively inhibited, and therefore autoimmune diseases are improved.

The invention discloses a genetically engineered bacterium for synthesizing N-acetyl blue as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium is prepared by knocking out a lactic dehydrogenase gene ldh and inserting a phosphoketolase gene xfpK on a knockout site, knocking out a pyruvate oxidase gene poxB and inserting a phosphate transacetylase gene pta on a knockout site of a microorganism for producing N-acetyl blue, and knocking out an aconitase inhibition factor gene acnR, inserting a glutamate dehydrogenase gene gdhA on a knockout site, knocking out a glutamine synthetase adenylation transferase gene glnE, and inserting an alpha-ketoglutarate dehydrogenase inhibition factor gene odhI on a knockout site to obtain the strain. According to the method, the supply of the precursor acetyl coenzyme A is enhanced by introducing a non-oxidative glycolysis pathway, the pH dynamic regulation system balances the metabolic flux, and the double breakthrough of the yield and the carbon recovery rate of the N-acetyl blue is realized by combining a two-stage fermentation process.

The invention discloses a high-deacetylation-degree chitosan preparation method, which comprises: suspending chitin in a solvent to prepare a chitin suspension; adding a compound enzyme into the obtained suspension liquid to carry out enzymatic reaction, so as to prepare the chitosan with high deacetylation degree; wherein the compound enzyme is prepared from chitin deacetylase, chitinase, beta-N-acetylglucosaminidase and protease. According to the method, four enzymes with complementary functions are creatively combined to form a unique technical path of four-stage synergistic interaction of'removal-deconstruction-assistant-deacetylation ', so that a natural chitin crystal barrier can be efficiently deconstructed, the protein shielding effect is overcome, and the effect of directly preparing high-deacetylation-degree chitosan from chitin is achieved.

To provide a new bitterness masking agent of potassium chloride, and to provide a production method or the like including the masking agent.SOLUTION: The bitterness masking agent of potassium chloride contains Balsam Peru essential oil as an active ingredient. Here, it is preferable to further contain at least one or more selected from the group consisting of arginine, glutamic acid, lysine and citrulline. It is also preferable to further contain at least one selected from the group consisting of acetoin, diacetyl, and 2, 3-pentanedione.SELECTED DRAWING: None

The invention discloses a recombinant bacterium for producing mevalonic acid by taking glucose and acetone as co-substrates as well as a construction method and application of the recombinant bacterium, and belongs to the technical field of genetic engineering. The problems that an existing mevalonic acid biosynthesis mode is low in carbon atom economy, limited in theoretical yield and the like are solved. According to the invention, acetone carboxylase, acetoacetyl coenzyme A synthetase, 3-hydroxy-3-methylglutaryl coenzyme A reductase and hydroxymethyl glutaryl-CoA synthetase are subjected to heterologous expression in escherichia coli with an acetyl coenzyme A acetyltransferase gene atoB and a histidine protein kinase gene atoS knocked out, and self carbonic anhydrase is over-expressed; and a new way for synthesizing MVA by using glucose and acetone as a co-substrate is constructed. According to the method, one molecule of CO2 can be fixed in the biosynthesis of mevalonic acid, the yield of carbon atoms in the synthesis process of mevalonic acid is increased, the problem of low yield of carbon atoms in the synthesis process of mevalonic acid by taking glucose as a single substrate is solved, and a new thought is provided for constructing a carbon neutralization type biological manufacturing technology.

The invention discloses a genetically engineered bacterium for producing heparinogen and a construction method and application thereof, the genetically engineered bacterium takes Escherichia coli Nissle 1917 as a chassis bacterium, and the construction method comprises the following steps: (1) knocking out endonuclease I coding gene endA in a chassis bacterium genome; (2) knocking out a 6-phosphofructokinase I coding gene pfkA in a chassis bacterium genome; (3) carrying out overexpression on a 6-phosphoglucosamine synthetase encoding gene glmS and / or a UDP-glucose-6-dehydrogenase encoding gene kfiD from a chassis bacterium genome; (4) removing the feedback inhibition of the 6-phosphate glucosamine on the GlmS so as to promote the synthesis of UDP-N-acetylglucosamine; and (5) knocking out the 6-phosphate glucosamine deaminase coding gene nagB in the chassis bacterium genome. The engineering strain obtained by the invention can more efficiently synthesize the proheparin, the shake flask titer reaches 397.9 mg / L, which is increased by about 3 times compared with a wild strain, and the engineering strain has certain industrial application value.

The present invention provides recombinant Corynebacterium glutamicum genetically engineered to introduce the N-acetylmannosamine (ManNAc) synthesis pathway, and genetically engineered to express an exogenous N-acetylneuraminic acid synthetase, an exogenous CMP-N-acetylneuraminic acid synthetase, an exogenous lactose transporter, and an exogenous sialyltransferase. The invention also provides a method for producing sialic acid lactose by using the recombinant corynebacterium glutamicum.

The present invention relates to a method for producing α-sialyl-β-D-galactoside saccharides, particularly α-sialyl-(2→3)-β-D-galactoside saccharides and α-sialyl-(2→6)-β-D-galactoside saccharides, from a β-D-galactoside saccharide, a sialic acid donor, and an enzyme with β-galactoside α-sialyltransferase activity. The enzymes with β-galactoside α-sialyltransferase activity used herein do not exhibit catalytic activity towards the hydrolysis of cytidine 5'-monophospho-N-acetyl-neuraminic acid to cytidine and N-acetyl-neuraminic acid. The method can be performed in vitro and in vivo using a genetically engineered cell comprising a nucleic acid encoding said enzyme. Further, said process may be adapted to produce the sialic acid donor CMP-Neu5Ac from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, a cytidine phosphate (CMP, CDP or CTP) and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), optional a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3).

Prodrugs of colchicine, de-acetyl colchicine, colcemid, and nocodazole are provided as therapies for the treatment of diseases ameliorated by the inhibition of microtubule polymerization.

The invention discloses a human-derived active composition co-loaded exosome for organoid screening and application thereof, belongs to the technical field of cosmetics, and particularly relates to a human-derived active composition co-loaded exosome. The human-derived active composition co-loaded exosome comprises an oil-phase outer shell which is modified by phospholipid polyethylene glycol polypeptide in a targeting manner, and a water-phase inner shell which wraps the oil-phase outer shell, the oil phase shell is an outer oil phase formed by self-assembly of an exosome-like shell composition; the water-phase inner shell is an inner water phase formed by an exosome-like inner core composition; the exosome-like in-vivo nucleus composition contains blue copper peptide and N-acetylneuraminic acid. According to the human-derived active composition co-loaded exosome disclosed by the invention, efficient co-loading encapsulation and stable delivery of blue copper peptide and N-acetylneuraminic acid are realized, and the anti-aging, anti-inflammatory and skin repairing effects of the human-derived active composition co-loaded exosome are remarkably improved.